PMID- 37845830
OWN - NLM
STAT- MEDLINE
DCOM- 20231228
LR  - 20240417
IS  - 1535-3699 (Electronic)
IS  - 1535-3702 (Print)
IS  - 1535-3699 (Linking)
VI  - 248
IP  - 20
DP  - 2023 Oct
TI  - Proteomics analysis of carotid body tumor revealed potential mechanisms and 
      molecular differences among Shamblin classifications.
PG  - 1785-1798
LID - 10.1177/15353702231199475 [doi]
AB  - Carotid body tumors (CBTs) are a rare type of paraganglioma, and surgical 
      resection is the only effective treatment. Because of the proximity of CBTs to 
      the carotid artery, jugular vein, and cranial nerve, surgery is extremely 
      difficult, with high risks of hemorrhage and neurovascular injury. The Shamblin 
      classification is used for CBT clinical evaluation; however, molecular mechanisms 
      underlying classification differences remain unclear. This study aimed to 
      investigate pathogenic mechanisms and molecular differences between CBT types. In 
      Shamblin I, II, and III tumors, differentially expressed proteins (DEPs) were 
      identified using direct data-independent acquisition (DIA). DEPs were validated 
      using immunohistochemistry. Proteomics profiling of three Shamblin subtypes 
      differed significantly. Bioinformatics analysis showed that adrenomedullin 
      signaling, protein kinase A signaling, vascular endothelial growth factor (VEGF) 
      signaling, ephrin receptor signaling, gap junction signaling, interleukin (IL)-1 
      signaling, actin cytoskeleton signaling, endothelin-1 signaling, angiopoietin 
      signaling, peroxisome proliferator-activated receptor (PPAR) signaling, bone 
      morphogenetic protein (BMP) signaling, hypoxia-inducible factor 1-alpha (HIF-1alpha) 
      signaling, and IL-6 signaling pathways were significantly enriched. Furthermore, 
      60 DEPs changed significantly with tumor progression. Immunohistochemistry 
      validated several important DEPs, including aldehyde oxidase 1 (AOX1), mediator 
      complex subunit 22 (MED22), carnitine palmitoyltransferase 1A (CPT1A), and heat 
      shock transcription factor 1 (HSF1). To our knowledge, this is the first 
      application of proteomics quantification in CBT. Our results will deepen the 
      understanding of CBT-related pathogenesis and aid in identifying therapeutic 
      targets for CBT treatment.
FAU - Lv, Yanze
AU  - Lv Y
AD  - Department of Vascular Surgery, State Key Laboratory of Complex Severe and Rare 
      Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 
      Sciences & Peking Union Medical College, Beijing 100730, China.
FAU - Gu, Guangchao
AU  - Gu G
AD  - Department of Vascular Surgery, State Key Laboratory of Complex Severe and Rare 
      Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 
      Sciences & Peking Union Medical College, Beijing 100730, China.
FAU - Zeng, Rong
AU  - Zeng R
AD  - Department of Vascular Surgery, State Key Laboratory of Complex Severe and Rare 
      Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 
      Sciences & Peking Union Medical College, Beijing 100730, China.
FAU - Liu, Zhili
AU  - Liu Z
AD  - Department of Vascular Surgery, State Key Laboratory of Complex Severe and Rare 
      Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 
      Sciences & Peking Union Medical College, Beijing 100730, China.
FAU - Wu, Jianqiang
AU  - Wu J
AUID- ORCID: 0000-0001-6773-9289
AD  - Clinical Research Institute, National Science and Technology Key Infrastructure 
      on Translational Medicine, State Key Laboratory of Complex Severe and Rare 
      Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 
      Sciences & Peking Union Medical College, Beijing 100730, China.
FAU - Zheng, Yuehong
AU  - Zheng Y
AUID- ORCID: 0000-0002-0704-5469
AD  - Department of Vascular Surgery, State Key Laboratory of Complex Severe and Rare 
      Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 
      Sciences & Peking Union Medical College, Beijing 100730, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231016
PL  - Switzerland
TA  - Exp Biol Med (Maywood)
JT  - Experimental biology and medicine (Maywood, N.J.)
JID - 100973463
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Humans
MH  - *Carotid Body Tumor/pathology/surgery
MH  - Proteomics
MH  - Vascular Endothelial Growth Factor A
MH  - Retrospective Studies
MH  - Carotid Arteries
MH  - Treatment Outcome
PMC - PMC10792421
OTO - NOTNLM
OT  - Carotid body tumor
OT  - Shamblin classification
OT  - mass spectrometry
OT  - pathogenesis
COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2023/10/17 06:42
MHDA- 2023/12/28 06:42
PMCR- 2024/04/16
CRDT- 2023/10/17 01:02
PHST- 2023/12/28 06:42 [medline]
PHST- 2023/10/17 06:42 [pubmed]
PHST- 2023/10/17 01:02 [entrez]
PHST- 2024/04/16 00:00 [pmc-release]
AID - 10.1177_15353702231199475 [pii]
AID - 10.1177/15353702231199475 [doi]
PST - ppublish
SO  - Exp Biol Med (Maywood). 2023 Oct;248(20):1785-1798. doi: 
      10.1177/15353702231199475. Epub 2023 Oct 16.